WHO对HPV疫苗质量安全性及有效性指导原则Word文件下载.docx
《WHO对HPV疫苗质量安全性及有效性指导原则Word文件下载.docx》由会员分享,可在线阅读,更多相关《WHO对HPV疫苗质量安全性及有效性指导原则Word文件下载.docx(5页珍藏版)》请在冰豆网上搜索。
![WHO对HPV疫苗质量安全性及有效性指导原则Word文件下载.docx](https://file1.bdocx.com/fileroot1/2022-10/11/a3620294-c975-40da-bea9-c627a8631c34/a3620294-c975-40da-bea9-c627a8631c341.gif)
1、生产方面:
VLP是复杂的生物产物,必须在不同水平下对其进行检测分析。
因而在其生产过程及质量控制上必须考虑以下几个因素:
1)新的表达体系如杆状病毒(GSK),新的特殊要求。
但我们用的毕赤酵母,相对比较常见。
2)新佐剂(略)
3)天然的L1蛋白是没有被糖基化修饰,目前的两种表达体系,在糖基化修饰上不存大问题,但要对糖基化及其位点进行分析。
4)L1衣壳蛋白亚单位的解聚与再聚,可能有利于纯化,并得到更稳定的VLP。
目前,我们的路线可能是不经解聚,直接纯化获得VLP。
个人感觉,到后期可以兵分两路,一路直接获得VLP,而另一路则将VLP解聚后,再进行纯化与重组。
5)纯化后的L1VLP要进行生化及免疫上的鉴定,并测定L1的浓度、纯度及组聚情况。
6)如加入了防腐剂,应对其免疫性进行验证,并确认不会有负作用
2、非临床方面:
关键就是要证明其免疫原性,并能否产生免疫中和抗体。
3、临床方面:
(略)
三、生产指导(PartA.Guidelinesonmanufacturing)
定义definitions
国际名称和专有名称
国际名称:
重组人乳头瘤类病毒颗粒疫苗(基因型16L1蛋白)
定义描述
重组HPVVLP疫苗为无菌的液态疫苗,里面含纯化后由一种或多种HPV基因型重组的主要的衣壳蛋白,并与相应佐剂混合。
国际标准品
在此指导原则编写时,市场上暂无国际标准品提供。
但有相应试剂在实验室水平上,在进行注射后进行生物效价方面的评价如抗体滴度和病毒DNA检测。
术语Terminology
Thedefinitionsgivenbelowapplytothisdocumentonly.
HPVL1protein:
Themajorstructuralproteinofhumanpapillomavirus,ofwhich360moleculesarefoundinthenativevirionassociatedin72pentamericcapsomers.
L1virus¬
likeparticle:
Anon¬
infectious,non¬
enveloped,icosahedralcapsidparticlewhichdoesnotcontainviralDNAandwhichiscomposedofregulararraysofL1pentamericcapsomers.
Parentalyeastcell:
Yeasthostcelltobemanipulatedfortheexpressionofprotein(s)togiverisetoarecombinantyeastproductionstrain.
Inoculumintermediate:
Aquantityofrecombinantbaculovirusofuniformcomposition,derivedfromtheworkingseedlot.Theinoculumintermediatehasadefinedshelf¬
life.ItisintendedtobeusedtoinitiatetheproductionofrecombinantL1proteins.
Cellbank:
Acollectionofampoulescontainingaliquotsofasuspensionofcellsfromasinglepoolofcellsofuniformcomposition,storedfrozenunderdefinedconditions(typically<
−60°
Cforyeast,andinliquidnitrogenforinsectormammaliancelllines).
Mastercellbank(MCB):
Acollectionofcontainerscontainingaliquotsofasuspensionofcellsfromasinglepoolofcellsofuniformcomposition,storedfrozenunderdefinedconditions(typically<
Cforyeast,andinliquidnitrogenforinsectormammaliancelllines).TheMCBisusedtoderiveallworkingcellbanksfortheanticipatedlifetimeofthevaccineproduct.
Workingcellbank(WCB):
Acollectionofcontainerscontainingaliquotsofasuspensionofcellsfromasinglepoolofcellsofuniformcomposition,derivedfromtheMCB,storedfrozenunderdefinedconditions(typically<
Cforyeast,andinliquidnitrogenforinsectormammaliancelllines).OneormorealiquotsoftheWCBareusedforroutineproductionofthevaccine.MultipleWCBsaremadeandusedduringthelifetimeofvaccineproduct
Productioncellculture:
AcellculturederivedfromoneormorecontainersoftheWCBusedfortheproductionofvaccines.
Endofproductioncells:
Acellsuspensioncontainingthecellsharvestedattheendofculture/fermentation.
Adventitiousagents:
Contaminatingmicroorganismsofthevirus,orcellsubstrateormaterialsusedintheircultures,thatmayincludebacteria,fungi,mycoplasmas,andendogenousandexogenousvirusesthathavebeenunintentionallyintroduced.
Fermentationcellpaste:
Asuspensionofcellsharvestedattheendoftheyeastfermentationstoredfrozen(<
¬
60°
C).
Singleantigenharvest:
Acell¬
suspensioncontainingtheintendedHPVantigensofonevirustypeharvestedfromcellculturespreparedfromasingleproductionrun
Singleharvestpool:
AhomogenouspoolofmultiplesingleharvestsoftheintendedHPVantigensofonevirustype,collectedintoasinglevesselbeforeclarification.
Purifiedmonovalentantigenbulk:
AbatchofpurifiedantigenofthesameHPVtype.Differentbatchesofpurifiedmonovalentantigenbulksmaybepooledbeforecollectionintoasinglevessel.
Adsorbedmonovalentantigenbulk:
Abatchofpurifiedmonovalentantigenbulkadsorbedonanaluminiumcontainingadjuvant.Differentbatchesofadsorbedmonovalentantigenbulksmaybepooledbeforecollectionintoasinglevessel.
Adjuvant:
Avaccineadjuvantisacomponentthatpotentiatestheimmuneresponsetoanantigenand/ormodulatesittowardsthedesiredimmuneresponses.
Finalvaccinebulk:
Theformulatedbulkpresentinthecontainerfromwhichthefinalcontainersarefilled.ThefinalbulkmaybepreparedfromoneormoreadsorbedmonovalentantigenbulksandmaycontainVLPantigensfromoneormultipleHPVvirustypes.
Fillinglot(finalvaccinelot):
Acollectionofsealedfinalcontainersofvaccinethatishomogeneouswithrespecttotheriskofcontaminationduringthefillingprocess.Afillinglotmustthereforehavebeenfilledorpreparedinoneworkingsession.
生产建议
生产必须符合GMP要求,生物安全上要求无菌。
不同类型HPVL1VLP应分别生产,同时,还要有充分的清洁验证。
抗原生产过程,须验证以证明生产的稳定性,至少要连续三批。
但如两种蛋白的纯化步骤一样,可只用验证一种。
生产一致性评估应包括关键质量参数评